Cargando…

A Novel Brighter Bioluminescent Fusion Protein Based on ZZ Domain and Amydetes vivianii Firefly Luciferase for Immunoassays

Immunoassays are widely used for detection of antibodies against specific antigens in diagnosis, as well as in electrophoretic techniques such as Western Blotting. They usually rely on colorimetric, fluorescent or chemiluminescent methods for detection. Whereas the chemiluminescence methods are more...

Descripción completa

Detalles Bibliográficos
Autores principales: Viviani, Vadim R., Silva, Jaqueline Rodrigues, Ho, Paulo Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558436/
https://www.ncbi.nlm.nih.gov/pubmed/34733833
http://dx.doi.org/10.3389/fbioe.2021.755045
_version_ 1784592560932519936
author Viviani, Vadim R.
Silva, Jaqueline Rodrigues
Ho, Paulo Lee
author_facet Viviani, Vadim R.
Silva, Jaqueline Rodrigues
Ho, Paulo Lee
author_sort Viviani, Vadim R.
collection PubMed
description Immunoassays are widely used for detection of antibodies against specific antigens in diagnosis, as well as in electrophoretic techniques such as Western Blotting. They usually rely on colorimetric, fluorescent or chemiluminescent methods for detection. Whereas the chemiluminescence methods are more sensitive and widely used, they usually suffer of fast luminescence decay. Here we constructed a novel bioluminescent fusion protein based on the N-terminal ZZ portion of protein A and the brighter green-blue emitting Amydetes vivianii firefly luciferase. In the presence of D-luciferin/ATP assay solution, the new fusion protein, displays higher bioluminescence activity, is very thermostable and produces a sustained emission (t(1/2) > 30 min). In dot blots, we could successfully detect rabbit IgG against firefly luciferases, Limpet Haemocyanin, and SARS-CoV-2 Nucleoprotein (1–250 ng), as well as the antigen bound antibodies using either CCD imaging, and even photography using smartphones. Using CCD imaging, we could detect up to 100 pg of SARS-CoV-2 Nucleoprotein. Using this system, we could also successfully detect firefly luciferase and SARS-CoV-2 nucleoprotein in Western Blots (5–250 ng). Comparatively, the new fusion protein displays slightly higher and more sustained luminescent signal when compared to commercial HRP-labeled secondary antibodies, constituting a novel promising alternative for Western Blotting and immunoassays.
format Online
Article
Text
id pubmed-8558436
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85584362021-11-02 A Novel Brighter Bioluminescent Fusion Protein Based on ZZ Domain and Amydetes vivianii Firefly Luciferase for Immunoassays Viviani, Vadim R. Silva, Jaqueline Rodrigues Ho, Paulo Lee Front Bioeng Biotechnol Bioengineering and Biotechnology Immunoassays are widely used for detection of antibodies against specific antigens in diagnosis, as well as in electrophoretic techniques such as Western Blotting. They usually rely on colorimetric, fluorescent or chemiluminescent methods for detection. Whereas the chemiluminescence methods are more sensitive and widely used, they usually suffer of fast luminescence decay. Here we constructed a novel bioluminescent fusion protein based on the N-terminal ZZ portion of protein A and the brighter green-blue emitting Amydetes vivianii firefly luciferase. In the presence of D-luciferin/ATP assay solution, the new fusion protein, displays higher bioluminescence activity, is very thermostable and produces a sustained emission (t(1/2) > 30 min). In dot blots, we could successfully detect rabbit IgG against firefly luciferases, Limpet Haemocyanin, and SARS-CoV-2 Nucleoprotein (1–250 ng), as well as the antigen bound antibodies using either CCD imaging, and even photography using smartphones. Using CCD imaging, we could detect up to 100 pg of SARS-CoV-2 Nucleoprotein. Using this system, we could also successfully detect firefly luciferase and SARS-CoV-2 nucleoprotein in Western Blots (5–250 ng). Comparatively, the new fusion protein displays slightly higher and more sustained luminescent signal when compared to commercial HRP-labeled secondary antibodies, constituting a novel promising alternative for Western Blotting and immunoassays. Frontiers Media S.A. 2021-10-18 /pmc/articles/PMC8558436/ /pubmed/34733833 http://dx.doi.org/10.3389/fbioe.2021.755045 Text en Copyright © 2021 Viviani, Silva and Ho. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Viviani, Vadim R.
Silva, Jaqueline Rodrigues
Ho, Paulo Lee
A Novel Brighter Bioluminescent Fusion Protein Based on ZZ Domain and Amydetes vivianii Firefly Luciferase for Immunoassays
title A Novel Brighter Bioluminescent Fusion Protein Based on ZZ Domain and Amydetes vivianii Firefly Luciferase for Immunoassays
title_full A Novel Brighter Bioluminescent Fusion Protein Based on ZZ Domain and Amydetes vivianii Firefly Luciferase for Immunoassays
title_fullStr A Novel Brighter Bioluminescent Fusion Protein Based on ZZ Domain and Amydetes vivianii Firefly Luciferase for Immunoassays
title_full_unstemmed A Novel Brighter Bioluminescent Fusion Protein Based on ZZ Domain and Amydetes vivianii Firefly Luciferase for Immunoassays
title_short A Novel Brighter Bioluminescent Fusion Protein Based on ZZ Domain and Amydetes vivianii Firefly Luciferase for Immunoassays
title_sort novel brighter bioluminescent fusion protein based on zz domain and amydetes vivianii firefly luciferase for immunoassays
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558436/
https://www.ncbi.nlm.nih.gov/pubmed/34733833
http://dx.doi.org/10.3389/fbioe.2021.755045
work_keys_str_mv AT vivianivadimr anovelbrighterbioluminescentfusionproteinbasedonzzdomainandamydetesvivianiifireflyluciferaseforimmunoassays
AT silvajaquelinerodrigues anovelbrighterbioluminescentfusionproteinbasedonzzdomainandamydetesvivianiifireflyluciferaseforimmunoassays
AT hopaulolee anovelbrighterbioluminescentfusionproteinbasedonzzdomainandamydetesvivianiifireflyluciferaseforimmunoassays
AT vivianivadimr novelbrighterbioluminescentfusionproteinbasedonzzdomainandamydetesvivianiifireflyluciferaseforimmunoassays
AT silvajaquelinerodrigues novelbrighterbioluminescentfusionproteinbasedonzzdomainandamydetesvivianiifireflyluciferaseforimmunoassays
AT hopaulolee novelbrighterbioluminescentfusionproteinbasedonzzdomainandamydetesvivianiifireflyluciferaseforimmunoassays